
New Best practice guidance on the sale of medicines for pain relief
The MHRA have updated their Blue Guide on Advertising and Promoting Medicines. The update is to Appendix 4 with new Best Practice guidance on the sale of medicines for pain relief.
The MHRA have updated their Blue Guide on Advertising and Promoting Medicines. The update is to Appendix 4 with new Best Practice guidance on the sale of medicines for pain relief.
The pharmaceutical wholesale industry is a dynamic and highly regulated field, requiring businesses to adhere to stringent compliance standards. Pharmacy Consulting Ltd (PCL) provides comprehensive support to help wholesalers navigate these complexities, offering expert guidance in obtaining and maintaining Wholesale Distribution Authorizations (WDA) and ensuring adherence to Good Distribution Practice (GDP) guidelines.
Given all the recent attention that has rightly been placed on the upcoming changes to medicinal products for the UK market, as a result of the implementation of parts of the Windsor Framework, it would be easy to assume that similar changes or at least thought processes would apply to other products.
In May 2024 the Veterinary Medicines Directorate (VMD) published and regarding the Veterinary Medicines Regulations 2013 (VMR). The Veterinary Medicines (Amendment etc.) Regulations 2024 are not effective but what does this mean for UK wholesalers?
Unless they appear on the NIMAR list, PLGB licensed medicines are not licensed in Northern Ireland. That means they are effectively supplied to NI as an Unlicensed ‘Special’.
After the implementation of the Windsor Framework, the Medicines and Healthcare products Regulatory Agency (MHRA) will license all medicines across the whole of the UK’.